Vyome Therapeutics targets malignant fungating wounds with its 1953 gel, addressing unmet medical needs. The company aims to create shareholder value by focusing on immuno-inflammation therapies. Their upcoming investor presentation will detail strategies for advancing various molecules and unlocking potential value.